Results from the second CONCORD study (CONCORD-2) indicated that 5-year net survival for lung cancer was low (range, 10%-20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range. METHODS: Data from CONCORD-2 were used to analyze net survival among patients with lung cancer (aged 15-99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state-specific and race-specific life tables and age-standardized using International Cancer Survival Standard weights. 2001-2003 and 2004-2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079-99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
INTRODUCTION
In the United States, lung cancer accounts for approximately 14% of all invasive cancers diagnosed each year and for 27% of all cancer-related deaths. 1 Lung cancer incidence and mortality rates vary by sex and race. 1,2 Among males, lung cancer incidence peaked in 1982, and mortality peaked in 1991. 2 Among females, mortality peaked in 2003, and incidence peaked in 2006. 2 Lung cancer incidence and mortality rates are currently decreasing slowly, but the rates are higher among black males than among white males and are lower among black females than among white females. 1, 2 By 2020, the numbers of lung cancer cases and deaths in the United States are projected to increase because of the aging white population and population growth in the black population. 3, 4 Population-based cancer survival provides an indicator of the overall effectiveness of the health care system to deliver screening, early diagnosis, and evidenced-based treatment services to all individuals in the population being served. 5 Survival differences between populations may be attributable to disparities in access to early diagnosis and optimal treatment. 6 The second CONCORD study (CONCORD-2) reported survival for patients diagnosed with cancer between 1995 and 2009 in 67 countries, enabling comparison of survival of patients in the United States with other countries. 6, 7 The CONCORD-2 study is the largest study to date on lung cancer survival, both in the United States and worldwide.
In the current study, we conduct a more detailed analysis of US data from the CONCORD-2 study. We describe and discuss trends in net survival among patients diagnosed with lung cancer by race, stage, and state. We also discuss how population-based lung cancer survival might be used to help inform comprehensive cancer control. 8 
MATERIALS AND METHODS

Data Source
We analyzed the US lung cancer data from the CONCORD-2 study, which included cases reported by 37 state-wide cancer registries funded by CDC's National Program of Cancer Registies (NPCR) and/or the National Cancer Institute's Surveillance Epidemiology and End Results Program (SEER), and that covered approximately 80% of the US population and consented to the inclusion of their data in the more detailed analyses reported here. 7, 8 We analyzed individual tumor records for adults (men and women, aged 15-99 years) who were diagnosed with a primary, invasive cancer of the lung or bronchus (International Classification of Diseases for Oncology, third edition, 9 topography codes: C34.0-C34.3 and C34.8-C34.9) between 2001 and 2009 and were followed until December 31, 2009 , regardless of whether the patient had had a previous cancer. If a patient was diagnosed with 2 or more cancers of the lung between 2001 and 2009, then we only considered the first cancer in the survival analyses.
We grouped patients by year of diagnosis into 2 calendar periods (2001-2003 and 2004-2009 ) to reflect changes in the methods used by US registries to collect Surveillance, Epidemiology, and End Results (SEER) Summary Stage 2000 (SS2000) at diagnosis. Between 2001 and 2003, most registries coded stage to SS2000 directly from the medical records. 10 Between 2004 and 2009, all registries derived SS2000 using the Collaborative Staging System. 11 
Survival Analyses
We analyzed net survival by race (all races, black, white), by stage (localized, regional, distant, unknown), state, and calendar period of diagnosis. We estimated net survival at 1, 3, and 5 years after diagnosis with 95% confidence intervals (CIs), using the Pohar Perme estimator. 7, 12 Net survival can be interpreted as the probability of surviving up to a given time since diagnosis, after controlling for other causes of death (background mortality). 7 To control for wide differences in background mortality between participating registries and over time, we constructed life tables of all-cause mortality in the general population of each state from the number of deaths and the population, by single year of age, sex, calendar year, and, where possible, by race (black or white), using a flexible Poisson model. 13 Methods for constructing life tables have been published. 14 We estimated net survival using 2 different methods, since follow time was different in the 2 calendar periods. For patients diagnosed between 2001 and 2003, we used the cohort approach, because all patients had been followed for at least 5 years by December 31, 2009 . We used the complete approach to estimate net survival for patients who were diagnosed between 2004 and 2009, because 5 years of follow-up data were not available for all patients. We estimated net survival for 5 age groups (ages 15-44, 45-54, 55-64, 65-74, and 75-99 years). We obtained agestandardized survival estimates using the International Cancer Survival Standard weights. 15 If 2 or more of the 5 age-specific estimates could not be obtained, then we present only the pooled, unstandardized survival estimate for all ages combined. We identify unstandardized survival estimates using italics in tables.
We present trends, geographic variations, and differences in age-standardized survival by race in bar charts and funnel plots. 16 Funnel plots of net survival for the 2 periods (2001-2003 and 2004-2009 ) provide insight into the variability of lung cancer survival by race and state. They indicate how much a particular survival estimate deviates from the pooled estimate for all registries combined, given the precision of each estimate. 7, 16 The pooled estimate for all US registries combined is shown as the "target" (horizontal line) in the funnel plot. More details on data and methods are provided in the accompanying article by Allemani et al. Five-year net survival in most Northeastern states was higher than the US pooled estimate between both 2001-2003 and 2004-2009 (Fig. 1) . In contrast, 5-year net survival in many states in the South, Midwest, and West was lower than the US estimate during both time periods. Between the periods 2001-2003 and 2004-2009 , the absolute change in 5-year net survival increased 0.4% to 6.3% in 35 states, with a small decrease (range, 0.2%-0.3%) in 2 states. The absolute increase was greater than 2.6% (the increase in the pooled US estimate) in most states in the Northeast. In contrast, the absolute increase was less than 2.6% in many states in the South, Midwest, and West. Figure 2 shows geographic and racial variation in 5-year net survival by state. Although net survival for lung cancer was generally low in all states, in both calendar periods, survival for black patients was lower than that for white patients; and, in most states, it was lower than the pooled estimate of US registries (see Fig. 2 , horizontal line in the funnel plot).
Funnel Plots of 5-Year Net Survival by State
DISCUSSION
This study provides lung cancer survival estimates by race and stage for 37 states, including 80% of the US population. Between 2004 and 2009, the US lung cancer 5-year net survival was at the high end of the range for many countries in the CONCORD-2 study 6 and was consistent with the 5-year relative survival estimates previously reported in the National Program of Cancer Registries and SEER registries. 2 Even for a lethal cancer like lung cancer, survival for blacks was lower than for whites (Table 2) , and this was true especially for those with localized cancer (Table 3) , for which surgery is the main treatment of curative intent. We observed that age-standardized 5-year net survival for lung cancer (19.0%) was 4.2% higher than that for liver cancer (14.8%) 18 but lower than for the other cancers addressed in this Supplement, including stomach cancer (29.0%), 19 ovarian cancer (41.0%), 20 cervical cancer (62.8%), 21 rectal cancer (64.0%), 22 colon cancer (64.6%), 23 acute lymphoblastic leukemia in children (88.1%), 24 breast cancer (88.6%), 25 and prostate cancer (96.9%).
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Between 2004 and 2009, we observed that 5-year net survival for all stages was 4.5% lower among blacks than among whites. The racial differences were even more marked for lung cancer diagnosed at local stage (9.9% lower among blacks), 4.7% lower among blacks diagnosed at regional stage, but essentially the same for patients diagnosed at distant stage (only 0.3% lower among blacks). Our results are consistent with other reports of racial disparities in lung cancer. Reviews suggest that the reasons for the wide racial disparities in lung cancer survival are complex and multifactorial, with contributions from treatment-related factors, such as physician-patient encounters and decision-making, and barriers to access to high-quality care, such as lower patient income or insurance coverage limits. [30] [31] [32] Unfortunately, although our study highlights 2 key determinants (race and stage) of survival differences between US states, it does not provide definite conclusions about all of the factors that may contribute to differences, because information on these factors is not available for all patients with cancer at a population-based level. It would be interesting to analyze the availability or receipt of optimal treatment by US state and race. This may be possible during the next cycle of CONCORD (CONCORD-3).
In most states, we observed small but consistent increases in 5- 33 intensity-modulated radiation therapy, 34 and targeted therapy, also referred to as precision or personalized treatment. 35, 36 We could not directly assess whether differential access to treatment by race contributed to the racial disparities in survival, because we did not have data on the treatment received by each patient; however, if "equal treatment [for lung cancer] yields equal outcome regardless of race," 37 then that is a plausible conclusion.
Survival can be improved if treatment can be provided when lung cancer is diagnosed at localized stage. 35, 38 For the cancers discussed in this Supplement, only patients diagnosed at localized stage with liver cancer had lower 5-year survival (25 39 for individuals at high risk for lung cancer, and is covered by Medicare. 40 However, early detection of lung cancer by screening is unlikely to have contributed to the increase in 5-year net survival that we observed for lung cancer, because low-dose CT scans were not broadly available or recommended between 2001 and 2009, 41 and the USPSTF recommendations and Medicare regulations were only issued later.
In our study, the overall proportion of cases with unknown stage decreased from 11.5% between 2001 and 2003 to 8.0% between 2004 and 2009. This is an encouraging finding, because accurate lung cancer staging 35 is needed to guide therapy selection. Although this decrease is consistent with an increase in accuracy over time in lung cancer staging, the observed changes could be an artifact related to changes in staging methods between the 2 calendar periods. In the alternative, cases with unknown stage could be missing at random when some centers did not provide the data; the overall survival for these cases likely would be similar to the average survival for all cases. Cases with unknown stage also could reflect data from patients who were not completely staged because they were not good candidates for clinical workup and treatment; the overall survival for these cases would be similar to that of patients with more advanced stage disease. Between 2004 and 2009, survival for patients with unknown stage in our study was lower than that for patients with local or regional stage disease but higher than that for those with distant stage disease; this pattern suggests that many of the unknown cases were likely similar to cases with a more advanced stage.
CDC Cancer Prevention and Control Programs
The National Comprehensive Cancer Control Program (NCCCP) supports state, tribal, and territory programs to Original Article develop cancer plans that design and implement activities in cancer prevention and control. 8, 42 State-specific data are critical to inform these cancer-control plans and activities.
Although research is conducted to improve clinical care and to reduce racial disparities, the greatest impact to reduce lung cancer incidence will come from cancercontrol efforts directed at primary prevention of established risk factors, such as cigarette smoking, 43 the inhalation of secondhand smoke by nonsmokers, 43 indoor radon (a leading cause of lung cancer among nonsmokers), 44 occupational exposures to carcinogens, 45 and air pollution. 45 To address lung cancer prevention, incidence and mortality, NCCCP programs develop detailed plans to prevent and control cancer for their communities, and most include objectives for reducing tobacco use and indoor radon exposure. For example, two-thirds of NCCCP programs include funding for tobacco control, such as supporting cessation services and smoke-free policies. 46 NCCCP programs work with a national network of partner organizations to reach populations that tend to be heavy smokers. 47 Continued and expanded access to tobacco-cessation services could increase abstinence rates and decrease lung cancer incidence further.
Several NCCCP programs support activities related to lung cancer screening, including awareness through health-care provider education, media campaigns, and surveys to better understand the status of lung cancer screening in their communities. 48 Continued and expanded incorporation of objectives related to USPSTF lung cancer screening recommendations into NCCCP cancer plans could increase early detection of lung cancer, thereby improving lung cancer survival. 39 NCCCP programs could use their experiences from other cancer screening programs to impact lung cancer screening rates at a population level. Furthermore, as lung cancer screening begins to be fully implemented in the United States, NCCCP programs might explore the use of patient navigators to coordinate and improve compliance with follow-up visits and annual repeated lung cancer screening.
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In the future, NCCCP programs also might consider the feasibility of monitoring and evaluating the quality of diagnostic, treatment, and survivorship services for patients with lung cancer. By improving understanding of lung cancer care and whether advances in care are differentially accessed, NCCCP programs may identify effective ways to improve lung cancer survival and reduce disparities in various communities.
NCCCP programs can use lung cancer net survival estimates for their states as an additional data resource to support cancer prevention and control. 5, 38, 50 Combined with data on cancer incidence and death rates, cancer survival measures can provide a more comprehensive picture of the burden of cancer in a population and can support public health efforts to reduce cancer health disparities.
5,38,50
Strengths and Limitations
The overview article 5 by Weir et al in this Supplement of Cancer describes the strengths and limitations that apply to all of the articles in the Supplement, including this analysis of lung cancer survival.
Conclusions
We observed that lung cancer survival improved slightly from 16 1,2 Lung cancer mortality trends mirror lung cancer incidence trends because of the high fatality rate and low survival for patients with lung cancer. 51 Given the low survival observed in all states, cancer-control efforts directed at primary prevention through control of well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer in the long term. Efforts directed at improving equality of access to treatment would be expected to reduce the racial differences in survival in the short to medium term. Workshop 
